EP3390666A4 - Compositions et méthodes de traitement de maladies rénales - Google Patents
Compositions et méthodes de traitement de maladies rénales Download PDFInfo
- Publication number
- EP3390666A4 EP3390666A4 EP16876548.5A EP16876548A EP3390666A4 EP 3390666 A4 EP3390666 A4 EP 3390666A4 EP 16876548 A EP16876548 A EP 16876548A EP 3390666 A4 EP3390666 A4 EP 3390666A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- compositions
- treatment
- methods
- kidney diseases
- kidney
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Public Health (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562267242P | 2015-12-14 | 2015-12-14 | |
PCT/US2016/066576 WO2017106292A1 (fr) | 2015-12-14 | 2016-12-14 | Compositions et méthodes de traitement de maladies rénales |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3390666A1 EP3390666A1 (fr) | 2018-10-24 |
EP3390666A4 true EP3390666A4 (fr) | 2019-08-07 |
Family
ID=59057520
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16876548.5A Pending EP3390666A4 (fr) | 2015-12-14 | 2016-12-14 | Compositions et méthodes de traitement de maladies rénales |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP3390666A4 (fr) |
JP (2) | JP7049247B2 (fr) |
CA (1) | CA3005249A1 (fr) |
WO (1) | WO2017106292A1 (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015187825A2 (fr) | 2014-06-03 | 2015-12-10 | University Of Massachusetts | Compositions et méthodes de modulation de l'expression de la dysferline |
GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
JP6867945B2 (ja) | 2014-10-03 | 2021-05-12 | コールド スプリング ハーバー ラボラトリー | 核内遺伝子出力の標的とされた増強 |
US10196639B2 (en) | 2015-10-09 | 2019-02-05 | University Of Southampton | Modulation of gene expression and screening for deregulated protein expression |
US11083745B2 (en) | 2015-12-14 | 2021-08-10 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of autosomal dominant mental retardation-5 and Dravet Syndrome |
US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
IL301053A (en) | 2017-01-23 | 2023-05-01 | Regeneron Pharma | HSD17B13 variants and their uses |
SG11201909453RA (en) | 2017-04-11 | 2019-11-28 | Regeneron Pharma | Assays for screening activity of modulators of members of the hydroxysteroid (17-beta) dehydrogenase (hsd17b) family |
GB2594767B (en) | 2017-08-25 | 2022-06-22 | Stoke Therapeutics Inc | Antisense oligomers for treatment of conditions and diseases |
JP7434151B2 (ja) | 2017-10-11 | 2024-02-20 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Pnpla3 i148mの変異を発現している患者の肝疾患の治療におけるhsd17b13の阻害 |
US20210246443A1 (en) * | 2018-06-08 | 2021-08-12 | University Of Massachusetts | Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells |
WO2020154462A1 (fr) * | 2019-01-23 | 2020-07-30 | Rogcon U.R., Inc. | Oligonucléotides antisens ciblant des introns de scn2a conservés |
WO2021034985A1 (fr) * | 2019-08-19 | 2021-02-25 | Stoke Therapeutics, Inc. | Compositions et méthodes pour moduler l'épissage et l'expression de protéines |
EP4126966A1 (fr) | 2020-03-31 | 2023-02-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Dépistage protéomique de maladies lysosomales |
JP2023525799A (ja) | 2020-05-11 | 2023-06-19 | ストーク セラピューティクス,インク. | 状態及び疾患の治療のためのopa1アンチセンスオリゴマー |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015035091A1 (fr) * | 2013-09-04 | 2015-03-12 | Cold Spring Harbor Laboratory | Réduction de dégradation d'arnm à médiation non-sens |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030224514A1 (en) * | 2002-05-31 | 2003-12-04 | Isis Pharmaceuticals Inc. | Antisense modulation of PPAR-delta expression |
US20060134670A1 (en) * | 2004-11-19 | 2006-06-22 | Fabrice Piu | Enabling tools to identify ligands for hormone nuclear receptors |
US20110269735A1 (en) * | 2010-04-19 | 2011-11-03 | Celera Corporation | Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof |
US20140128449A1 (en) * | 2011-04-07 | 2014-05-08 | The Board Of Regents Of The University Of Texas System | Oligonucleotide modulation of splicing |
WO2014078749A1 (fr) * | 2012-11-15 | 2014-05-22 | The Regents Of The University Of California | Oligonucléotides modulant l'épissage qui inhibent le cancer |
JP6867945B2 (ja) * | 2014-10-03 | 2021-05-12 | コールド スプリング ハーバー ラボラトリー | 核内遺伝子出力の標的とされた増強 |
-
2016
- 2016-12-14 WO PCT/US2016/066576 patent/WO2017106292A1/fr active Application Filing
- 2016-12-14 EP EP16876548.5A patent/EP3390666A4/fr active Pending
- 2016-12-14 CA CA3005249A patent/CA3005249A1/fr active Pending
- 2016-12-14 JP JP2018529237A patent/JP7049247B2/ja active Active
-
2022
- 2022-02-01 JP JP2022013876A patent/JP2022062143A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015035091A1 (fr) * | 2013-09-04 | 2015-03-12 | Cold Spring Harbor Laboratory | Réduction de dégradation d'arnm à médiation non-sens |
Also Published As
Publication number | Publication date |
---|---|
JP2022062143A (ja) | 2022-04-19 |
CA3005249A1 (fr) | 2017-06-22 |
EP3390666A1 (fr) | 2018-10-24 |
JP2019500346A (ja) | 2019-01-10 |
JP7049247B2 (ja) | 2022-04-06 |
WO2017106292A1 (fr) | 2017-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3390666A4 (fr) | Compositions et méthodes de traitement de maladies rénales | |
EP3368559A4 (fr) | Compositions et méthodes pour le du traitement du cancer | |
EP3389672A4 (fr) | Compositions et procédés de traitement de maladies hépatiques | |
EP3390634A4 (fr) | Compositions et méthodes pour le traitement de maladies oculaires | |
EP3389725A4 (fr) | Compositions et méthodes pour le traitement de maladies du système nerveux central | |
EP3347469A4 (fr) | Méthodes et compositions pour le traitement du glaucome | |
EP3177732A4 (fr) | Compositions et procédés pour le traitement de maladies et états pathologiques ophthalmiques | |
EP3426250A4 (fr) | Procédés de traitement | |
EP3668993A4 (fr) | Procédés de traitement de maladies hépatiques | |
EP3341392A4 (fr) | Compositions et procédés de traitement de la douleur | |
EP3256113A4 (fr) | Traitement de l'hypoparathyroïdie | |
EP3096617A4 (fr) | Compositions et méthodes de traitement de maladies oculaires | |
EP3139928A4 (fr) | Compositions d'anordrine et méthodes de traitement de maladies | |
EP3139935A4 (fr) | Compositions placentaires thérapeutiques, procédés de fabrication et méthodes d'utilisation | |
EP3353204A4 (fr) | Méthodes et compositions pour le traitement du cancer | |
EP3131556A4 (fr) | Méthodes et compositions pour le traitement de maladies liées à la bpco | |
EP3253211A4 (fr) | Compositions et méthodes pour traiter l'oedème | |
EP3340974A4 (fr) | Méthodes de traitement de maladies | |
EP3253401A4 (fr) | Méthode de traitement de maladies | |
EP3484526A4 (fr) | Compositions et méthodes destinées au traitement de maladies cardiaques | |
EP3481958A4 (fr) | Procédés et compositions de traitement de troubles et de maladies impliquant rdh12 | |
EP3185910A4 (fr) | Méthodes et compositions pour le traitement du cancer | |
EP3419638A4 (fr) | Compositions et procédés de traitement de maladies infectieuses chroniques | |
EP3164132A4 (fr) | Méthodes et compositions pour le traitement de maladies et d'affections | |
IL259710A (en) | Preparations and methods for the treatment of Davidson's disease (microvillus inclusion disease) and related diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20180706 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: C12Q0001680000 Ipc: C12N0015113000 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20190709 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 15/11 20060101ALI20190703BHEP Ipc: C12N 15/52 20060101ALI20190703BHEP Ipc: C12N 15/113 20100101AFI20190703BHEP |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1262956 Country of ref document: HK |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: NASH, HUW M. Inventor name: KRAINER, ADRIAN Inventor name: AZNAREZ, ISABEL |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20200527 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230922 |